Clinical trial
Phase II Study to Evaluate the Efficacy of AMG 317
NCT00436670 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00436670 |
|---|---|
| Title | Phase II Study to Evaluate the Efficacy of AMG 317 |
| Official title | A Randomized, Double-blind, Placebo-controlled, Multiple Dose Phase 2 Study to Determine the Safety and Efficacy of AMG 317 in Subjects With Moderate to Severe Asthma |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Biological |
| Interventions | AMG 317 75 mg, AMG 317 150 mg, AMG 317 300 mg, Placebo |
| Enrollment | 294 |
| Start date | Mar 1, 2007 |
| Primary completion | Sep 1, 2008 |
| Completion | Feb 1, 2009 |
| First posted | Feb 19, 2007 |
| Last update posted | Mar 23, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: